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ATA TGC ATC TGG CAG CCA TC-39. DNA amplification
was performed in a PTC–100 thermocycler from M.J. Research
(MA), programmed as follows: 120 s at 96°C initial to cycling,
5 cycles of 30 s at 96°C, 30 s at 55°C, and 30 s at 72°C
followed by 25 cycles of 30 s at 96°C and 30 s at 72°C, with
a final extension at 72°C for 10 min. Sequence analysis of the
polymerase chain reaction fragment using BigDye fluorescent
labelled M13 primers was performed on an Applied Biosystems
377 A automated DNA sequencer following the manufacturer’s
protocols (PE Applied Biosystems, Foster City, CA).
The clinical symptoms and the family history of our patients
strongly pointed to the diagnosis of SLS. FALDH activity was
severely deficient in both patients, with a value of 3.3 and
0.0 pmol per min mg protein in patients 1 and 2, respectively
(median FALDH activity in 13 healthy controls: 40.9, range
19.7–54.3 pmol per min mg protein). In both children we
detected a homozygous 4 bp deletion (1384–1387delGAAA) in
exon 9 of the FALDH gene, and heterozygosity was demonstrated
in their parents (Fig 1).
FALDH is a membrane-bound protein with a highly hydro-
phobic amino acid sequence at the carboxy-terminal region,
which is assumed to be necessary for microsomal membrane
anchoring (Masaki et al, 1994; Chang and Yoshida, 1997; Rogers
et al, 1997). The 1384–1387delGAAA mutation leads to
replacement of the carboxy-terminal amino acids [462-
EKLGLLLLTFLGIVAAVLVKAEYY-485] by [462-NSVSCCSLS-
WVL-473], and premature termination of translation at codon
474. The deleted amino acids contain a predicted transmembrane
domain (amino acids 464–480) and membrane retention signal
[481-KAEY-484]. It is likely that the mutation results in a
truncated FALDH that no longer can be anchored to the
microsomal membrane, leading to deficient enzyme activity and
the classical clinical symptoms of SLS.
An alternatively spliced product of the FALDH gene is known,
which contains an additional 125 nucleotides (designated 99)
between exon 9 and exon 10 (Rogers et al, 1997). The mutation
occurs upstream of exon 99, for which reason it will similarly
compromise the translation of both transcripts.
This study contributes to the elucidation of the genetic
backgrounds of SLS, and points to the vital importance of
membrane anchoring for the preservation of FALDH activity.
Promoter/Enhancer Cassettes for Keratinocyte Gene Therapy
To the Editor:
Successful keratinocyte gene therapy requires that transcriptional
units express the therapeutic gene properly in keratinocytes in vivo.
Promoter/enhancer cassettes containing these units should be
examined under in vivo conditions (Cheng et al, 1993). In this
study, we transferred plasmids that were constructed by introducing
various promoter/enhancer cassettes fused with the lacZ (reporter)
gene into keratinocytes by direct injection of naked DNA (Hengge
et al, 1995), and evaluated the cassettes by measuring β-galactosidase
(β-gal) expression.
Plasmid pNASSβ (CLONTECH, Palo Alto, CA) was a pro-
moterless expression vector of the lacZ gene that contained a simian
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virus 40 (SV40) RNA splice site, which is an SV40 polyadenylation
signal. For convenience, we refer to this plasmid as pZ(–). To
synthesize the promoter segments of the mouse 230 kDa bullous
pemphigoid antigen 1 gene, we carried out polymerase chain
reaction (PCR) using a mouse bullous pemphigoid antigen 1 gen-
omic clone as a template (Sawamura et al, 1994). The DNA
segments extending from –1133 to –1, –525 to –1, and 213 to –1
were inserted into pZ(–) to produce p1.1 BPZ, p0.5 BPZ, and
p0.2 BPZ, respectively. We synthesized the promoter segments of
the human K5 and K10 genes by PCR using human genomic
DNA as a template. The K5 and K10 DNA fragments that extended
from –840 to –1 (Ohtuki et al, 1992) and from –1200 to –1 (Rieger
and Franke, 1988), respectively, were inserted into pZ(–) to produce
pK5Z and pK10Z, respectively. All PCR products were sequenced
and no PCR errors were detected from comparisons with the
original sequences. Plasmids pAGS-lacZ and pCMS-lacZ contained
the chicken modified β-actin promoter and 660 bp HincII-HindIII
cytomegalovirus-immediate early (CMV-IE) enhancer/promoter,
respectively (Miyazaki et al, 1989), and these two promoters were
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followed by lacZ and a SV40 polyadenylation signal. The HincII-
NcoI region of the CMV-IE enhancer was introduced directly into
the XhoI site, using a SalI linker, located the 59-end of the β-actin
Figure 1. Comparison of the b-gal activities in keratinocytes in vivo
after transfer of various constructs. The following constructs were
used for this experiment: (A) pZ(–), p0.2 BPZ, p0.5 BPZ, p1.1 BPZ,
pK5Z, and pK10Z; (B) pSV40S-lacZ, pCMS-lacZ, pAGS-lacZ, pK10S-
lacZ, pK10Z, pRS-lacZ, pCAGS-lacZ, and pCAGGS-lacZ (see the text).
β-Gal activity was assayed 24 h after transfer and the β-gal activities of
these constructs were expressed relative to (A) that of pK10Z(*) and (B)
that of pK10S-lacZ(*). Each value represents the mean 6SD of six
individual samples.
Figure 2. The amount of transgene in keratinocytes after gene
transfer. The amount of transgene was measured semiquantitatively 24 h
after the introduction of various constructs. After PCR amplification of
the 567 bp fragment of the lacZ gene in the treated keratinocytes,
the amount of each PCR product was estimated by 1.2% agarose gel
electrophoresis. M, size marker; 1, phosphate-buffered saline as negative
control; 2, pAGS-lacZ; 3, pCAGS-lacZ; 4, pCAGGS-lacZ; 5, pCMS-lacZ.
promoter in pAGS-lacZ, and resulted in pCAGS-lacZ (Niwa et al,
1991). Plasmids pSV40S-lacZ and pK10S-lacZ were produced by
replacing the XhoI-HindIII fragment of the β-actin promoter in
pAGS-lacZ with the SV40 early promoter and the 1.2 kb K10
fragment, respectively. Plasmid pCAGGS-lacZ was constructed by
replacing a SV40 polyadenylation signal with a 39-flanking sequence
of the rabbit β-globin gene, which included a polyadenylation
signal (Niwa et al, 1991). Plasmid Rous sarcoma (pRS)-lacZ was
constructed by replacing the HindIII-BamHI fragment, including
the chloramphenicol acetyltransferase gene, of pRSV-cat (Gorman
et al, 1982) with lacZ. Each plasmid DNA was purified by
equilibrium centrifugation in CsCl-ethidium bromide gradients and
two or three plasmid preparations were used for the experiments.
Hirosaki hairless rats were used for these experiments (Sawamura
et al, 1997). The required plasmid was diluted with phosphate-
buffered saline to produce a DNA concentration of 100 ng per µl,
and 30 µl (total amount, 3 µg) was injected as superficially as
possible into the subepidermal dermis using a 30-gauge needle. At
various times after transfer, 6 mm punch biopsy specimens were
obtained from the transfected area.
The β-gal activities in the rat keratinocytes were quantitated
using our previous method (Sawamura et al, 1997), with certain
modifications. Epidermal sheets were obtained from the 6 mm
punch biopsy samples by 10 mg per ml dispase treatment (3 h at
37°C), and keratinocyte suspensions were obtained from these
epidermal sheets by 0.25% trypsin treatment (30 min at 37°C).
The keratinocytes were lyzed in 40 µl lysis buffer, centrifuged at
12,000 r.p.m. for 2 min, and a 5 µl aliquot of the resulting cell
extract was assayed using the Luminescent β-Galactosidase Genetic
Reporter System (CLONTECH) and a chemiluminometer to
measure the chemiluminescence. The β-gal activity was expressed
as light units per µg protein (Protein Assay Kit, BIO-RAD,
Heracles, CA). Six separate samples from one experiment were
subjected to this assay. We repeated the experiments at least three
times to confirm their reproducibility.
Epidermal sheets from the injected area were obtained after
dispase treatment, then digested with trypsin, washed three times
extensively with phosphate-buffered saline, lyzed in 40 µl lysis
buffer, and centrifuged for 2 min. A 2 µl aliquot of each cell extract
was used as a template and then PCR was performed to measure
the lacZ gene in the cells semiquantitatively. We used two primers,
59-GACGATGGTGCAGGATATCC-39 and 59-ACTGACGAA-
ACGCCTGCCAG, to amplify the 567 bp lacZ segment that
extended from 1430 to 1996 (MacGregor and Caskey, 1989). The
amount of each PCR product was estimated by 1.5% agarose
gel electrophoresis and ethidium bromide staining. Before the
experiment we established the PCR conditions that resulted in
exponential amplification.
Plasmids p0.2 BPZ, p0.5 BPZ, p1.1 BPZ, pK5Z, pK10Z, and
pZ(–) had identical plasmid backbones (Fig 1A). Plasmids pSV40S-
lacZ, pCMS-lacZ, pAGS-lacZ, pCAGS-lacZ, pK10S-lacZ, and
pRS-lacZ shared a different plasmid backbone (Fig 1B). The β-actin
promoter with CMV-IE enhancer and the 39-flanking sequence of
the rabbit β-globin gene in pCAGGS-lacZ were also examined,
although its backbone was different from those of the first two
groups (Fig 1B). The β-gal activity was assayed 24 h after transfer
and the β-gal activities of these constructs were expressed relative
to those of K10 constructs, pK10Z in Fig 1(A) and pK10S-lacZ
in Fig 1(B).
Figure 1 shows that the specific β-gal activities of these constructs
varied. Of the promoters expressed virtually almost specifically in
keratinocytes, the K10 promoter resulted in relatively high-level
β-gal expression, whereas bullous pemphigoid antigen 1 promoter
had a weak effect (Fig 1A). Of the viral promoters, the CMV-IE
promoter exhibited much higher activity than the SV40 promoter
(Fig 1B) and the RS virus long-terminal repeat. Because the CMV-
IE promoter was strongest among the simple promoters that were
excised from original genes, we examined two other constructs,
pCAGS-lacZ and pCAGGS-lacZ, to determine the effects of the
CMV-IE enhancer and the 39-flanking sequence of the rabbit
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β-globin gene on the transcriptional activity of keratinocytes. The
activity of pCAGS-lacZ was about 15 times greater than that of
pAGS-lacZ and that of pCAGGS was about two and six times
those of pCAGS-lacZ and pCMS-lacZ, respectively (Fig 1B).
The amount of transgene was measured semiquantitatively 24 h
after the introduction of various constructs. We introduced pAGS-
lacZ, pCAGS-lacZ, pCAGGS-lacZ, and pCMS-lacZ, and per-
formed PCR amplification of the lacZ gene. We also injected
phosphate-buffered saline as a control. The result showed no clear
differences among the band intensities of the PCR products
(Fig 2A), and the amounts of the transgene (lacZ) in the ker-
atinocytes into which these plasmids introduced could not reflect
a difference among the activities of the plasmids. We detected no
bands in the sample of phosphate-buffered saline. We sequenced
the PCR products and digested with appropriate restriction enzymes
to test for PCR specificity (data not shown).
Cheng et al (1993) carried out similar experiments using particle
bombardment to introduce genes, and showed that the CMV-IE
promoter was very active in keratinocytes. We also found that the
CMV-IE promoter in pCMS-lacZ exhibited very high activity
(Fig 1). We also evaluated the activities of the promoter from
genes that were specifically expressed in keratinocytes and found
that the K10 promoter in pK10Z showed the highest activity
(Fig 1A); however, the K10 promoter in pK10S-lacZ was still
weaker than the CMV-IE promoter in pCMS-lacZ. Our results
demonstrate that the CMV-IE promoter was superior to the other
simple promoters, with respect to the activity level. In an attempt
to take advantage of the highly active viral CMV-IE promoter, we
assayed the activity of pCAGS. This construct was tested using
several types of cell in culture; enhancement of expression was
observed in L and CHO cells, but not in F9 cells (Niwa et al, 1991).
The addition of CMV-IE enhancer increased β-gal expression in
keratinocytes in vivo 15-fold. The 39-flanking sequence of the
rabbit β-globin gene was used for the construction of expression
vectors in several groups and these vectors exhibited high levels of
production of the inserted gene in various cells (Niwa et al, 1991;
Karasuyama and Melchers, 1988). We also tested the activity of
pCAGGS-lacZ, in which 39-flanking sequence of the rabbit
β-globin gene was introduced into the 39-end of the lacZ gene,
resulting in a further 2-fold enhancement. We could not make
precise comparisons among pCAGGS-lacZ and the other constructs
because of different backbones, but pCAGGS-lacZ exhibited the
highest activity for all the constructs tested. We constructed an
interleukin-10 expression vector using this cassette, introduced it
into keratinocytes in vivo by direct injection of naked DNA, and
achieved systemic expression of transgenic interleukin-10 (Meng
Interaction of BP180 and a6b4
To the Editor:
In a recent issue of the journal, Hopkinson et al (1998) have
reported studies aimed at assessing the interaction potential of
BP180 with the α6 integrin subunit, and they raised concerns
about the consistency and validity of previous data published by
our and other groups on this subject. Because several statements
appear at best to be polemic due to the authors’ unwillingness to
thoroughly review work of other investigators, rather than
Manuscript received December 22, 1998; revised January 4, 1999;
accepted for publication January 19, 1999.
et al, 1998). This study has provided useful information for
developing potential promoter/enhancer cassettes for keratinocyte
gene therapy using the direct injection of naked DNA method.
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addressing the potential complex mechanisms involved in the
assembly of hemidesmososmes, some clarifications are required.
These authors emphasize a first contradiction between their data
and our findings on page 1017, where it is stated that a fragment
of BP180, containing the complete cytoplasmic domain, the
transmembrane domain, and a short region of the extracellular
domain, does not autoactivate transcription of reporter genes in
yeast. In the authors’ interpretations, these results contradict our
findings, which indicated that a fragment of BP180 containing the
complete cytoplasmic domain without the transmembrane domain
cannot be used in the yeast-two hybrid assay because of autoactiv-
ation. It is obvious, however, that the cDNA clones of BP180 used
in these two studies cannot be directly compared. In addition, we
